Published in Lipids Health Dis on September 17, 2016
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem (1980) 7.03
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology (2012) 2.85
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology (2010) 2.67
Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr (2003) 2.44
Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes (2005) 2.43
De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr (1999) 2.28
Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab (2003) 2.21
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci U S A (2000) 2.10
Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest (1996) 2.05
Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr (2007) 2.04
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut (2010) 1.84
Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol (1992) 1.81
Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia (2011) 1.80
Positional and positioning vertigo and nystagmus. J Neurol Sci (1990) 1.73
Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest (1999) 1.70
Dietary sugars stimulate fatty acid synthesis in adults. J Nutr (2008) 1.66
Regulation of acetyl-CoA carboxylase. Biochem Soc Trans (2006) 1.64
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013) 1.56
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.55
Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest (1995) 1.55
Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr (2008) 1.54
Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab (2006) 1.54
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol (2015) 1.50
In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am J Physiol (1994) 1.48
Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.40
Influence of virgin coconut oil-enriched diet on the transcriptional regulation of fatty acid synthesis and oxidation in rats - a comparative study. Br J Nutr (2014) 1.38
Hormonal control of ketogenesis. Biochemical considerations. Arch Intern Med (1977) 1.38
Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A (2011) 1.32
Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care (2013) 1.32
Glycogen storage capacity and de novo lipogenesis during massive carbohydrate overfeeding in man. Am J Clin Nutr (1988) 1.26
Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J Lipid Res (2006) 1.23
Effect of alterations of the specific activity of the intracellular acetyl CoA pool on apparent rates of hepatic cholesterogenesis. J Lipid Res (1974) 1.21
De novo lipogenesis in health and disease. Metabolism (2014) 1.20
Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem (2009) 1.20
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr (1999) 1.16
Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res (2010) 1.15
A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab (2011) 1.14
Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes (2012) 1.13
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr (2014) 1.08
Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res (2008) 1.08
Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. Int J Obes Relat Metab Disord (2004) 1.05
Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men. Am J Clin Nutr (2001) 1.04
Consumption of plant sterols reduces plasma and hepatic triglycerides and modulates the expression of lipid regulatory genes and de novo lipogenesis in C57BL/6J mice. Mol Nutr Food Res (2010) 1.00
Increased dietary substrate delivery alters hepatic fatty acid recycling in healthy men. Diabetes (2005) 0.97
Glycogen synthesis versus lipogenesis after a 500 gram carbohydrate meal in man. Metabolism (1982) 0.96
Use of mass isotopomer distributions in secreted lipids to sample lipogenic acetyl-CoA pool in vivo in humans. Am J Physiol (1991) 0.95
Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism. J Anim Sci (2006) 0.93
The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients (2014) 0.93
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res (2008) 0.92
Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia (2009) 0.89
Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo. Clin Lipidol (2009) 0.89
Recent advances in lipidomics for disease research. J Sep Sci (2015) 0.86
Tracing lipogenesis in humans using deuterated water. Can J Physiol Pharmacol (1996) 0.86
Measurement of human lipogenesis using deuterium incorporation. J Lipid Res (1993) 0.85
Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans. Am J Physiol Endocrinol Metab (2010) 0.84
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci (2016) 0.83
Effect of randomly interesterified triacylglycerols containing medium- and long-chain fatty acids on energy expenditure and hepatic fatty acid metabolism in rats. Biosci Biotechnol Biochem (2005) 0.83
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem (2014) 0.82
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia (2016) 0.82
Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice. Genes Nutr (2015) 0.81
De novo lipogenesis in metabolic homeostasis: More friend than foe? Mol Metab (2015) 0.81
Medium-chain fatty acids as short-term regulators of hepatic lipogenesis. Biochem J (1994) 0.80
Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men. J Clin Endocrinol Metab (2015) 0.80
Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World J Gastroenterol (2015) 0.78
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab (2016) 0.77
Molecular mechanisms of fatty liver in obesity. Front Med (2015) 0.77
Desaturation index versus isotopically measured de novo lipogenesis as an indicator of acute systemic lipogenesis. BMC Res Notes (2015) 0.77
Use of deuterium oxide to measure de novo fatty acid synthesis in normal subjects consuming different dietary fatty acid composition1. Biochim Biophys Acta (1998) 0.77
Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease. Nutr Res (2015) 0.76
Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. PLoS One (2015) 0.76
Increased serum levels of lipogenic enzymes in patients with severe liver steatosis. Lipids Health Dis (2012) 0.75